Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Head & Neck 9Thoracic 6Lymphoid 4Other solid neoplasm 2Endocrine 2Breast 2Sarcoma 1Other neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Neoplasm Metastasis 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
penpulimab × Endocrine × Clear all
NCT06062563 2023-10-02

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Peking Union Medical College Hospital

Phase NA Unknown
10 enrolled
EndocrineHead & Neck

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Peking Union Medical College Hospital

Phase 2 Unknown
5 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡